financetom
Business
financetom
/
Business
/
Merger-Bound Berry Global Agrees To Divest Specialty Tapes Unit For ~$540M
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Merger-Bound Berry Global Agrees To Divest Specialty Tapes Unit For ~$540M
Nov 26, 2024 8:39 AM

Berry Global Group, Inc. ( BERY ) shares are trading lower on Tuesday. On Monday, the company disclosed an agreement to sell its Specialty Tapes business to Nautic Partners, LLC, for around $540 million, subject to closing adjustments.

The divestment aligns with its strategy of focusing on higher-growth, consumer-oriented markets. The company plans to use proceeds from the sale to reduce debt.

The sale is expected to close in the first half of 2025, subject to customary closing conditions.

Including the cash received from its recent HHNF spin-off and the Tapes sale, Berry's pro forma net debt as of September 30, 2024, is expected to be approximately $5.9 billion, representing a 3.5x LTM net leverage ratio.

Berry CEO, Kevin Kwilinski, said, “Over the past year, Berry has undergone a significant transformation, completing the spin-off of our HHNF business, enhancing our product mix and optimizing our portfolio. The sale of Tapes further supports these efforts and the continued focus on our high-growth consumer portfolio.”

This month, Berry Global ( BERY ) agreed to merge with Amcor plc ( AMCCF ) in an all-stock transaction, with the deal valuing Berry stock at $73.59 per share.

The companies anticipate a $650 million benefit from synergies by the end of year three, including $530 million in annual pre-tax cost savings, $60 million in financial savings, and $60 million from growth synergies.

Berry Global ( BERY ) noted the sale of the Tapes business further reinforces the strategic rationale for the combination and has no material impact on the financial profile of the combined entity.

Price Action: BERY shares are down 1.47% at $70.50 at the last check Tuesday.

Read Next:

Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Siemens's share slump to one-year low after CFO's gloomy outlook
Siemens's share slump to one-year low after CFO's gloomy outlook
Mar 19, 2024
(Reuters) - Shares in Siemens slumped to their lowest in one year after its finance chief Ralf Thomas commented that revenues at its flagship digital industries division will be flat in the second quarter at a Bank of America ( BAC ) conference on Tuesday. Thomas said the German technology conglomerate forecasts revenue at the division to be a good...
Fastenal Insider Sold Shares Worth $832,453, According to a Recent SEC Filing
Fastenal Insider Sold Shares Worth $832,453, According to a Recent SEC Filing
Mar 19, 2024
09:37 AM EDT, 03/19/2024 (MT Newswires) -- Charles S. Miller, SENIOR EXECUTIVE VP, on March 15, 2024, sold 11,076 shares in Fastenal ( FAST ) for $832,453. Following the Form 4 filing with the SEC, Miller has control over a total of 13,151 shares of the company, with 13,151 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/815556/000141588924008305/xslF345X03/form4-03182024_090342.xml Price: 75.43, Change: -0.27, Percent...
Mastercard Partners With Alipay for Global Fund Transfers to China
Mastercard Partners With Alipay for Global Fund Transfers to China
Mar 19, 2024
09:36 AM EDT, 03/19/2024 (MT Newswires) -- Mastercard ( MA ) said Tuesday it has partnered with Alipay for global fund transfers to China. Financial terms weren't disclosed. Alipay is a Chinese digital open platform under Ant Group, the company added. Price: 479.93, Change: +1.03, Percent Change: +0.22 ...
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
Mar 19, 2024
Tuesday, Seelos Therapeutics Inc ( SEEL ) provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial.  The study was designed to evaluate SLS-005 (IV trehalose), a low molecular weight disaccharide that stabilizes misfolded proteins and activates autophagy, in decreasing the slope of the ALS Functional Rating Scale (ALSFRS-R) and separation from placebo in Function and Mortality in an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved